# Angiodynamics Inc: overview

ANGO · Nasdaq · CIK 1275187 · [Healthcare](/sectors/healthcare.md) · fiscal year ends May 31

Pages: [Overview](/companies/ango.md) · [Financials](/companies/ango/financials.md) · [Filings](/companies/ango/filings.md) · [Insiders](/companies/ango/insiders.md)

Latest reported revenue: [$80.9m](/filings/0001628280-26-065423.md) for Q1 FY2027, three months to 2026-08-31, from the 10-Q filed Oct 8, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001628280-26-065423).

## Last eight quarters

| Line item | Unit | Q2 FY2025 (2024-11-30) | Q3 FY2025 (2025-02-28) | Q4 FY2025 (2025-05-31) | Q1 FY2026 (2025-08-31) | Q2 FY2026 (2025-11-30) | Q3 FY2026 (2026-02-28) | Q4 FY2026 (2026-05-31) | Q1 FY2027 (2026-08-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [72.8](/filings/0001275187-26-000003.md) | [72.0](/filings/0001628280-26-023008.md) | [80.2 d](/filings/0001628280-26-048138.md) | [75.7](/filings/0001628280-26-065423.md) | [79.4](/filings/0001275187-26-000003.md) | [78.4](/filings/0001628280-26-023008.md) | [86.6 d](/filings/0001628280-26-048138.md) | [80.9](/filings/0001628280-26-065423.md) |
| Gross margin | % | [54.8%](/filings/0001275187-26-000003.md) | [54.0%](/filings/0001628280-26-023008.md) | [52.7% d](/filings/0001628280-26-048138.md) | [55.3%](/filings/0001628280-26-065423.md) | [56.4%](/filings/0001275187-26-000003.md) | [52.9%](/filings/0001628280-26-023008.md) | [54.0% d](/filings/0001628280-26-048138.md) | [59.4%](/filings/0001628280-26-065423.md) |
| Operating margin | % | [(15.2%)](/filings/0001275187-26-000003.md) | [(13.9%)](/filings/0001628280-26-023008.md) | [(7.2%) d](/filings/0001628280-26-048138.md) | [(14.1%)](/filings/0001628280-26-065423.md) | [(7.7%)](/filings/0001275187-26-000003.md) | [(16.5%)](/filings/0001628280-26-023008.md) | [(11.8%) d](/filings/0001628280-26-048138.md) | [(9.0%)](/filings/0001628280-26-065423.md) |
| Net margin | % | [(14.7%)](/filings/0001628280-26-023008.md) | [(6.1%)](/filings/0001628280-26-023008.md) | [(7.5%) d](/filings/0001140361-26-037995.md) | [(14.4%)](/filings/0001628280-26-065423.md) | [(8.0%)](/filings/0001628280-26-023008.md) | [(10.3%)](/filings/0001628280-26-023008.md) | [(13.2%) d](/filings/0001140361-26-037995.md) | [(8.8%)](/filings/0001628280-26-065423.md) |
| Diluted EPS | $ per share | [(0.26)](/filings/0001275187-26-000003.md) | [(0.11)](/filings/0001628280-26-023008.md) | not reported | [(0.26)](/filings/0001628280-26-065423.md) | [(0.15)](/filings/0001275187-26-000003.md) | [(0.19)](/filings/0001628280-26-023008.md) | not reported | [(0.17)](/filings/0001628280-26-065423.md) |
| Free cash flow | $m | [1.7 d](/filings/0001275187-26-000003.md) | [(15.0) d](/filings/0001628280-26-023008.md) | [18.0 d](/filings/0001628280-26-048138.md) | [(16.6)](/filings/0001628280-26-065423.md) | [4.2 d](/filings/0001275187-26-000003.md) | [(4.1) d](/filings/0001628280-26-023008.md) | [17.0 d](/filings/0001628280-26-048138.md) | [(15.7)](/filings/0001628280-26-065423.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 6-month figure less the 3-month figure; 9-month figure less the 6-month figure; 12-month figure less the 9-month figure.

## Last five fiscal years

| Line item | Unit | FY2022 (2022-05-31) | FY2023 (2023-05-31) | FY2024 (2024-05-31) | FY2025 (2025-05-31) | FY2026 (2026-05-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [316](/filings/0001628280-24-032989.md) | [339](/filings/0001275187-25-000014.md) | [304](/filings/0001628280-26-048138.md) | [292](/filings/0001628280-26-048138.md) | [320](/filings/0001628280-26-048138.md) |
| Gross margin | % | [52.4%](/filings/0001628280-24-032989.md) | [51.4%](/filings/0001275187-25-000014.md) | [50.9%](/filings/0001628280-26-048138.md) | [53.9%](/filings/0001628280-26-048138.md) | [54.6%](/filings/0001628280-26-048138.md) |
| Operating margin | % | [(9.0%)](/filings/0001628280-24-032989.md) | [(15.1%)](/filings/0001275187-25-000014.md) | [(63.3%)](/filings/0001628280-26-048138.md) | [(13.7%)](/filings/0001628280-26-048138.md) | [(12.5%)](/filings/0001628280-26-048138.md) |
| Net margin | % | [(8.4%)](/filings/0001140361-26-037995.md) | [(15.5%)](/filings/0001140361-26-037995.md) | [(60.7%)](/filings/0001140361-26-037995.md) | [(11.6%)](/filings/0001140361-26-037995.md) | [(11.5%)](/filings/0001140361-26-037995.md) |
| Diluted EPS | $ per share | [(0.68)](/filings/0001628280-24-032989.md) | [(1.33)](/filings/0001275187-25-000014.md) | [(4.59)](/filings/0001628280-26-048138.md) | [(0.83)](/filings/0001628280-26-048138.md) | [(0.88)](/filings/0001628280-26-048138.md) |
| Free cash flow | $m | [(11.5)](/filings/0001628280-24-032989.md) | [(3.7)](/filings/0001275187-25-000014.md) | [(30.7)](/filings/0001628280-26-048138.md) | [(14.6)](/filings/0001628280-26-048138.md) | [0.5](/filings/0001628280-26-048138.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/ango/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $49.5m | 3,803,232 |  | Added +117,328 |
| [Point72 Asset Management, L.P.](/funds/1603466.md) | 2026-06-30 | $39.8m | 3,062,517 |  | Reduced −119,312 |
| [SYSTEMATIC FINANCIAL MANAGEMENT LP](/funds/1085936.md) | 2026-06-30 | $34.3m | 2,640,214 |  | Added +186,513 |
| [ARMISTICE CAPITAL, LLC](/funds/1601086.md) | 2026-06-30 | $28.6m | 2,198,000 |  | Added +329,000 |
| [ROYCE & ASSOCIATES LP](/funds/906304.md) | 2026-06-30 | $25.6m | 1,969,835 |  | Added +440,884 |
| [Broadfin Holdings LLC](/funds/2110839.md) | 2026-06-30 | $23.7m | 1,818,533 |  | Reduced −250,800 |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $22.0m | 1,694,716 |  | Reduced −32,104 |
| [WEBER CAPITAL MANAGEMENT LLC /ADV](/funds/1099905.md) | 2026-06-30 | $17.6m | 1,356,602 |  | Reduced −16,547 |
| [Nuveen, LLC](/funds/1871926.md) | 2026-06-30 | $15.6m | 1,199,358 |  | Reduced −16,807 |
| [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $13.3m | 1,020,658 |  | Added +35,235 |

## Recent filings

[All 1,149 filings](/companies/ango/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-10-08 | 12:56 ET | [10-Q](/filings/0001628280-26-065423.md) | Quarterly report, period 2026-08-31 | 0001628280-26-065423 |
| 2026-10-08 | 08:16 ET | [DEF 14A](/filings/0001140361-26-039022.md) | Proxy statement, period 2026-11-17 | 0001140361-26-039022 |
| 2026-10-08 | 07:17 ET | [8-K](/filings/0001140361-26-039020.md) | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001140361-26-039020 |
| 2026-10-08 | 07:16 ET | [8-K](/filings/0001140361-26-039019.md) | 1.01 Entry into a material agreement; 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001140361-26-039019 |
| 2026-09-29 | 16:01 ET | [10-K/A](/filings/0001140361-26-037995.md) | Annual report, amended, period 2026-05-31 | 0001140361-26-037995 |
| 2026-09-29 | 09:14 ET | [10-K/A](/filings/0001140361-26-037943.md) | Annual report, amended, period 2026-05-31 | 0001140361-26-037943 |
| 2026-07-14 | 15:42 ET | [10-K](/filings/0001628280-26-048138.md) | Annual report, period 2026-05-31 | 0001628280-26-048138 |
| 2026-07-14 | 07:30 ET | [8-K](/filings/0001140361-26-028368.md) | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001140361-26-028368 |
| 2026-04-23 | 16:59 ET | [8-K](/filings/0001140361-26-016424.md) | 8.01 Other events | 0001140361-26-016424 |
| 2026-04-02 | 13:56 ET | [10-Q](/filings/0001628280-26-023008.md) | Quarterly report, period 2026-02-28 | 0001628280-26-023008 |

## Latest annual report

[Form 10-K for the fiscal year ended May 31, 2026](/filings/0001628280-26-048138.md), filed Jul 14, 2026.

## Forecast league

Not in this season’s league. [This season’s league](/leagues.md)

## About the filer

- CIK: 1275187
- Tickers: ANGO
- Exchange: Nasdaq
- SIC code: 3841 Surgical & Medical Instruments & Apparatus
- State of incorporation: DE
- Filer category: Accelerated filer

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 29, 2026, 16:03 ET. No prices; not investment advice.